Optimizing T cell immune response to cancer using IL-1R1 and its ligands
Using the IL-1R1 and its ligands to optimize the T cell immune response to cancer
This study is looking at how certain proteins in the immune system can help T cells fight cancer better, and it’s for anyone interested in new ways to improve cancer treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10931686 on NIH RePORTER |
What this research studies
This research investigates how the IL-1R1 receptor and its ligands can enhance the immune response of T cells against cancer. By examining the roles of IL-1α and IL-1β, the study aims to understand how blocking these molecules can improve T cell activation and modify the tumor microenvironment to favor anti-cancer immunity. The approach involves using mouse models to explore the complex interactions between these cytokines and T cells, with the goal of developing more effective cancer immunotherapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with various types of cancer who may benefit from improved immunotherapy options.
Not a fit: Patients with non-cancerous conditions or those who do not have a strong immune response may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for cancer by enhancing the body's immune response.
How similar studies have performed: Previous studies, such as the CANTOS trial, have shown promising results in blocking IL-1β and its association with reduced cancer incidence, indicating potential for success in similar approaches.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Kupper, Thomas S. — Brigham and Women's Hospital
- Study coordinator: Kupper, Thomas S.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.